newsfilter
← Latest News
ClinicalTrials.gov·

A Study of Retifanlimab After Chemoradiation in People With Anal Cancer - NCT07927998

Sponsor: Memorial Sloan Kettering Cancer Center Conditions: Anal Squamous Cell Carcinoma, Anal Cancer, Anal Carcinoma Participants will receive retifanlimab during 28-day treatment Cycles and will continue to receive retifanlimab for up to 6 Cycles (up to 12 Cycles with study doctor approval) unless the participant's cancer comes back, have serious side effects and cannot continue study treatment, or the study doctor thinks it is in the participant's best interest to stop.

Company
Memorial Sloan Kettering Cancer Center
Keywords
Anal Squamous Cell Carcinoma, Anal Cancer, Anal Carcinoma, Anal Squamous Cell Carcinoma, Anal Cancer, Anal Carcinoma, Memorial Sloan Kettering Cancer Center, 26-298